Manufacturer of Controlled Substances Notice of Registration, 77257-77258 [2011-31773]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 238 / Monday, December 12, 2011 / Notices
The company plans to import small
quantities of the listed controlled
substances for the National Institute on
Drug Abuse (NIDA) for research
activities.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate, 72 FR 3417
(2007). Regarding all other basic classes
of controlled substances, no comments
or objections have been received. DEA
has considered the factors in 21 U.S.C.
823(a) and 952(a) and determined that
the registration of Research Triangle
Institute to import the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. DEA has
investigated Research Triangle Institute
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: December 5, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
jlentini on DSK4TPTVN1PROD with NOTICES
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 15,
2011, Johnson Matthey Pharma
Services, 70 Flagship Drive, North
Andover, Massachusetts 01845, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Schedule
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Hydrocodone (9193) .....................
VerDate Mar<15>2010
15:55 Dec 09, 2011
II
II
II
Jkt 226001
Dated: December 5, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–31771 Filed 12–9–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
[FR Doc. 2011–31767 Filed 12–9–11; 8:45 am]
Drug
The company plans to utilize this
facility to manufacture small quantities
of the listed controlled substances in
bulk and to conduct analytical testing in
support of the company’s primary
manufacturing facility in West Deptford,
New Jersey. The controlled substances
manufactured in bulk at this facility will
be distributed to the company’s
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 10, 2012.
By Notice dated August 10, 2011, and
published in the Federal Register on
August 18, 2011, 76 FR 51400,
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambridge Isotope Lab to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
investigated Cambridge Isotope Lab to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
77257
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: December 5, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–31774 Filed 12–9–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Registration
By Notice dated August 10, 2011, and
published in the Federal Register on
August 18, 2011, 76 FR 51401, Chemica,
316 West 130th Street, Los Angeles,
California 90061, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Methamphetamine (1105), a basic class
of controlled substance listed in
schedule II.
The above listed controlled substance
is an intermediate in the manufacture of
Benzphetamine, a schedule III nonnarcotic controlled substance. The
company plans to utilize a bulk active
pharmaceutical ingredient (API) as an
intermediate for the development of
another controlled substance, and
further distribution to its customers.
The methamphetamine will not be sold
as a commercial product.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Chemica to manufacture the listed basic
class of controlled substance is
consistent with the public interest at
this time. DEA has investigated Chemica
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
E:\FR\FM\12DEN1.SGM
12DEN1
77258
Federal Register / Vol. 76, No. 238 / Monday, December 12, 2011 / Notices
Dated: December 5, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: December 5, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–31773 Filed 12–9–11; 8:45 am]
[FR Doc. 2011–31768 Filed 12–9–11; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Office of Justice Programs
Manufacturer of Controlled
Substances; Notice of Registration
[OMB Number 1121–0142]
By Notice dated August 8, 2011, and
published in the Federal Register on
August 18, 2011, 76 FR 51402, Lin Zhi
International Inc., 670 Almanor Avenue,
Sunnyvale, California 94085, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
jlentini on DSK4TPTVN1PROD with NOTICES
Tetrahydrocannabinols (7370) .....
3,4Methylenedioxymethamphetamine (7405).
Cocaine (9041) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
I
I
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances as bulk
reagents for use in drug abuse testing.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Lin
Zhi International Inc., to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lin Zhi International Inc.,
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. § 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
VerDate Mar<15>2010
15:55 Dec 09, 2011
Jkt 226001
Agency Information Collection
Activities; Proposed Collection;
Comments Requested: Extension of a
Currently Approved Collection; Victim
of Crime Act, Crime Victim Assistance
Grant Program, Subgrant Award
Report
ACTION: 60-Day Notice of Information
Collection Under Review.
Department of Justice (DOJ), Office of
Justice Programs (OJP), Office for
Victims of Crime (OVC) will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies. Comments
are encouraged and will be accepted for
‘‘sixty days’’ until February 10, 2012.
This process is conducted in accordance
with 5 CFR 1320.10.
If you have comments especially on
the estimated public burden or
associated response time, suggestions,
or need a copy of the proposed
information collection instrument with
instructions or additional information,
please contact DeLano Foster (202) 616–
3612, Office for Victims of Crime, Office
of Justice Programs, U.S. Department of
Justice, 810 7th Street NW., Washington,
DC 20531.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address one or more
of the following four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agencies
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection:
Victims of Crime Act, Victim Assistance
Grant Program, Subgrant Award Report.
(3) Agency form number, if any, and
the applicable component of the
Department of Justice sponsoring the
collection: Form number: 1121–0142.
Office for Victims of Crime, Office of
Justice Programs, U.S. Department of
Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: State government.
Other: None. The VOCA, Crime Victim
Assistance Grant Program, Subgrant
Award Report is a required submission
by state grantees, within 90 days of their
awarding a subgrant for the provision of
crime victim services. VOCA and the
Program Guidelines require each state
victim assistance office to report to OVC
on the impact of the Federal funds, to
certify compliance with the eligibility
requirements of VOCA, and to provide
a summary of proposed activities. This
information will be aggregated and serve
as supporting documentation for the
Director’s biennial report to the
President and to the Congress on the
effectiveness of the activities supported
by these grants.
This request is for an extension of a
currently approved reporting
instrument, with no revisions.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond/reply: The number of VOCAfunded victim assistance programs
varies widely from State to State. A
review of information currently
available to this Office on the number of
active victim assistance programs in 15
states selected for variance in size and
population revealed that a State would
be responsible for entering subgrant data
for as many as 499 programs (California)
to as few as 9 programs (District of
Columbia).
The estimated time to enter a record
via the Grants Management System is
E:\FR\FM\12DEN1.SGM
12DEN1
]]>Agencies
[Federal Register Volume 76, Number 238 (Monday, December 12, 2011)]
[Notices]
[Pages 77257-77258]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-31773]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances Notice of Registration
By Notice dated August 10, 2011, and published in the Federal
Register on August 18, 2011, 76 FR 51401, Chemica, 316 West 130th
Street, Los Angeles, California 90061, made application by renewal to
the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of Methamphetamine (1105), a basic class of controlled
substance listed in schedule II.
The above listed controlled substance is an intermediate in the
manufacture of Benzphetamine, a schedule III non-narcotic controlled
substance. The company plans to utilize a bulk active pharmaceutical
ingredient (API) as an intermediate for the development of another
controlled substance, and further distribution to its customers. The
methamphetamine will not be sold as a commercial product.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Chemica to manufacture the listed basic class of controlled substance
is consistent with the public interest at this time. DEA has
investigated Chemica to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above
named company is granted registration as a bulk manufacturer of the
basic class of controlled substance listed.
[[Page 77258]]
Dated: December 5, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-31773 Filed 12-9-11; 8:45 am]
BILLING CODE 4410-09-P
